FDA requiring lower recommended dose for certain sleep drugs containing zolpidem

The U.S. Food and Drug Administration today announced it is requiring the manufacturers of Ambien, Ambien CR, Edluar and Zolpimist, widely used sleep drugs that contain the active ingredient zolpidem, to lower current recommended doses. Ambien and Ambien CR are also available as generics. New data show that zolpidem blood levels in some patients may be high enough the morning after use to impair activities that require alertness, including driving.

Mobius Therapeutics, LLC Issues a Voluntary Recall of Mitosol® (mitomycin for solution), 0.2 mg/vial, Kit for Ophthalmic Use

On 10 January 2013, Mobius Therapeutics, LLC, St. Louis, MO, announced today that it is conducting a voluntary recall of 2 lots of Mitosol® (mitomycin for solution), 0.2 mg/vial, Kit for Ophthalmic Use. The company is taking this voluntary action due to the fact that we cannot exclude the possibility that the affected lots may be non-sterile.